Sign inJoin free

Watch / Biotech

Cashed-up and pairing with Merck

22 Mar 20246:41

Cashed-up and pairing with Merck

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Marc Voigt, CEO of Immutep, shares details about the company's latest drug development efforts. Immutep’s lead medicine candidate FTI is currently tested in various clinical trials for non-small cell lung cancer, head, neck, and metastatic breast cancers. In the trials for metastatic breast cancer, early results have been promising and well tolerated by the patients.

Tested in combination with Merck’s Keytruda and traditional chemotherapy, FTI triggers the patient's immune system to fight cancer. Immutep not only develops drugs for cancer treatment, but also has ongoing projects for treating autoimmune diseases. It's upcoming drug IMP 76, aimed for clinical trials by mid-year, is expected to aid in the control and treatment of autoimmune diseases.

Marc also clarifies that while being profitable is essential, their primary focus is delivering efficient results in sizable clinical trials. He further points out Immutep's significant achievements, including being the first Australian Biotech company to present late-breaking oral presentations at esteemed clinical oncology conferences, as well as the impressive doubling of median overall survival during non-small cell lung cancer clinical trials.

Below is the full unedited transcript of this interview:

0:00

Let's get company specific now and catch up with Biotech Immutep, which has a new drug candidate that's in late stage clinical trials for an update. We are joined by the chief executive, Marc Voigt. Marc, good to see you. Thank you for having me. You've joined us from Berlin, so I'm interested to see what your update is then. Just as far as you obviously trialing a number of drugs. What's the latest development. Yeah. Thank you. So indeed we have a lead product candidate called FTI, which we have in different clinical trials and non-small cell lung cancer in head and neck cancer and then metastatic breast cancer. And we have actually been releasing some results from metastatic breast cancer about two weeks ago. And what are those results been? Yeah, these results have been very encouraging. Six patients. So not a lot, but they are pointing into the right direction. The first time that we test flag mode with 90mg. So a higher dose. And we actually saw in pretreated patients in this very tough indication

1:00

a complete response. And the drug itself was very well tolerated. So it's very good. So just to be clear is this being used in combination with Keytruda which is from Merck. Um, that actually well it lifts the efficacy of the delivery of that drug. Does it a true indeed. So Keytruda, the top selling drug over all indications of all diseases in the world. We are testing it together with Keytruda in non-small cell lung cancer, neck cancer in metastatic breast cancer, though, we are testing together with traditional chemotherapy so we can combine if the lucky mode. It's a very versatile product with a variety of different other drugs, and this is what you typically try to do in order to achieve the best outcome for patients. So this actually stimulates the immune system of the patient then to fight cancer. Exactly. This is how it works. There are different therapies trying to achieve the same thing we are directed to, if you like, the general

2:00

of the immune system, those cells, antigen presenting cells which are informing other cells to actively fight cancer, provide the right information and help the other cells to divide, to proliferate, to become more. And those are the T cells. So we have a unique and effective way to boost the patient's immune system to actively fight cancer. You can actually measure that in patients. So what's your timeline on your clinical trials at the moment? You mentioned you've had six patients. What's the next step in metastatic breast cancer. It's we are currently in the phase two stage. So we are recruiting 58 patients. This is ongoing. And then we will see results round about mid of this year. And we have other trials ongoing in lung cancer. And predominantly that's one of the next milestones in first line at the neck cancer

2:52

back image has what you would refer to as a diversified product portfolio. What are some of your other developments? Yeah, we are also active in autoimmune diseases. So oncology is of course very important. We have three programs in oncology and two programs in autoimmune diseases. And we plan to bring our newest member of our drug family into clinical development by mid of this year. This will be an autoimmune diseases. The name of the product is IMP 76 one and an autoimmune diseases. You first of all go in healthy volunteers. You check for safety. And of course you will also try to detect the biological activity. Because ecology would like to have an active immune system and an autoimmune diseases, you would like to bring it under control because it's obviously, um, overreacting and attacking your own organ systems.

3:45

My biotech tends to be notoriously difficult, particularly in terms of raising capital doesn't because of those binary outcomes. Um, how well are you funded at the moment? Oh, we are very well funded. So we have more than 100 million AUD cash on bank and off last quarter. Um, the past two years have been more difficult for the healthcare industry overall. If you look at the stock markets, um, this has been changing earlier this year, and actually we are very, um, thankful for the support we have been getting out of Australia and internationally from our investors. We have a very strong register with a number of institutional investors also, of course, retail investors. So while the industry overall had difficulties, we haven't had difficulties mid of last year to raise a substantial amount of cash, around about 80 million AUD. And we are of course very prudent in terms of our cash management. There's not a single dollar to base. It should go to the clinical trials to the patients first of all. So that's a key exercise in our industry.

4:45

If the times are good or bad, you have to take responsibility for the budget and you have to maintain a healthy balance sheet in order to be in a position to move forward. And given that, and what do investors want to see before they actually commit that capital? Given it is so much. This is based around results from trials. What step do you need to reach before you actually bring investors on board and ultimately obviously looking to be profitable? Yeah, indeed. First of all, your last aspect first profitable. You need to look what is typically the commercial endpoint of the biotech industry. That is not the patient. So usually a biotech company does not bring the medicine to the patient themselves. They are not commercializing. But the endpoint is typically the big pharmaceutical industry. So companies could be acquired. You could do licensing transactions. This all can happen. It's a it's a standard in the market. What do investors need to see. They

5:44

prefer, I believe, to see clinical data so that the product has been tested in patients, that the proof of concept has been achieved. And in our case, it's maybe fair to say that we presented at the best international clinical oncology conferences very convincing data in oral presentation. So less than 0.1% of companies are getting those spots. We have been the first Australian biotech company, for instance, to present Late-breaking oral presentation at CTC, a big conference in which took place in Boston. Um, so that's important that you can deliver also in sizable clinical trials and first line non-small cell lung cancer, we had 114 patients. And we, by the way, doubled the median overall survival compared to Keytruda top selling drug in the world. Very powerful change the day to day clinical care. But in our clinical trial we doubled median overall survival, which is a very strong statement.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy